Private M&A 2024: Key Trends and Forecasts
What Goes On Inside Your Boardroom? Investors Want To Know
Public M&A Day in Frankfurt
Global Dealmaking in 2013: Why the Best Strategies will Dominate
As the slowdown in dealmaking continues, both buyers and sellers are left to consider their options moving forward during this period of extreme uncertainty and market volatility. To put the current slowdown in perspective,...more
Acquisition market participants in the U.S. approached dealmaking with greater caution in 2022 than they did in 2021. Steadily rising interest rates and financing costs, persistent inflation, geopolitical uncertainty,...more
In line with overall M&A trends, global private equity had a blockbuster 2021 by any metric, but perhaps the best is this: In a record-setting year for global M&A, a record was also set for the percentage of M&A deals that...more
Navigating the ever-changing global life sciences deal landscape has become more challenging in the post-pandemic world. Conducting virtual inspections and examining security and privacy risks for remote working and new...more
The outbreak of the novel coronavirus disease 2019 (COVID-19) and the measures being taken at every level to contain the spread thereof is a rapidly evolving public health and humanitarian issue. Naturally, COVID-19 and its...more
In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors are often unable to spend as much time on due diligence as they might like. Market players are often highly focused on the...more
James D. Rosener, Pepper Hamilton partner and chair of the firm's New York office and International Practice Group, presented at the opening roundtable of The Deal Economy 2013. When it comes to cross-border M&A, U.S....more